Current oncology最新文献

{"title":"Mortality-Related Risk Factors in Patients with Hematologic Neoplasm Admitted to the Intensive Care Unit: A Systematic Review.","authors":"Jhon H Quintana, Cesar David López-Vanegas, Giovanna Patricia Rivas-Tafurt, Leidy Tatiana Ordoñez-Mora, Heiler Lozada-Ramos, Jorge Enrique Daza-Arana","doi":"10.3390/curroncol32030132","DOIUrl":"10.3390/curroncol32030132","url":null,"abstract":"<p><strong>Background: </strong>Hematooncology patients admitted to intensive care units (ICUs) are at high risk for mortality due to the severity of their critical illness. Such complications can develop into complex clinical management, thus signaling an urgent need to identify mortality-related factors to improve interventions and outcomes for these patients.</p><p><strong>Methods: </strong>A systematic review of studies published between 2012 and 2023 in databases such as PubMed, Scopus, and Web of Science was conducted, following the PRISMA guidelines. A meta-analysis was carried out to determine the significance of mortality-related factors.</p><p><strong>Results: </strong>In a review of twenty-four studies, it was found that invasive mechanical ventilation (IMV) was associated with an odds ratio (OR) between 2.70 and 8.26 in 75% of the studies. The use of vasopressor support had an OR of 6.28 in 50% of the studies, while pulmonary involvement by tumor had an OR of 6.73 in 30% of the studies. Sepsis showed an OR of 5.06 in 60% of the studies, and neutropenia upon admission increased mortality in 40% of the studies. Severe respiratory failure (PaO₂/FiO₂ < 150) had an OR of 7.69 in 55% of the studies. Additionally, ICU readmission and late admission were identified as risk factors for increased mortality.</p><p><strong>Conclusions: </strong>Mortality among hematooncology ICU patients is associated with IMV, vasopressor support, pulmonary involvement, sepsis, neutropenia, severe respiratory failure, ICU readmission, and late admission. Identifying and managing these factors in a timely manner can improve survival and the quality of care.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PTSD in Patients Who Undergo Head and Neck Cancer Treatment: A Systematic Review.","authors":"Orli Weiss, Juliana Runnels, Daniel R Dickstein, Kristin Hsieh, Lauren Jacobs, Anuja Shah, Danielle Arons, Samuel Reed, Kunal K Sindhu, Richard Bakst, Julie Bloom","doi":"10.3390/curroncol32030134","DOIUrl":"10.3390/curroncol32030134","url":null,"abstract":"<p><strong>Background/objectives: </strong>Post-traumatic stress disorder (PTSD) can develop after exposure to real or perceived threats to life and is characterized by symptoms including intrusive thoughts, hyperarousal, and emotional numbness. While PTSD is well-studied in populations affected by disasters and combat, the impact of serious medical conditions like cancer and its treatments remain under-researched. Due to the aggressive nature of the disease, fear of recurrence, and disfiguring nature of treatments, patients with head and neck cancer (HNC) may experience a real or perceived risk of death. This systematic review synthesizes current knowledge on PTSD in patients with HNC.</p><p><strong>Methods: </strong>A systematic review was conducted per PRISMA guidelines. Five databases (PubMed, EMBASE, SCOPUS, CINAHL, and COCHRANE) were searched for studies describing PTSD in patients with and survivors of HNC. Studies with PTSD diagnosis and/or symptom data specific to patients with HNC were included.</p><p><strong>Results: </strong>Of 80 studies, 14 met the inclusion criteria. The most commonly used scale was the PTSD Checklist-Civilian Version. The prevalence of PTSD ranged from 8% to 41% across the studies. No significant differences were found with regards to PTSD prevalence by HNC tumor site, disease stage, or treatment modality. Two studies identified significant associations between PTSD after treatment and depression at the time of diagnosis. Patients with PTSD who received cognitive behavioral therapy showed improvement in their PTSD symptoms compared to those who did not.</p><p><strong>Conclusions: </strong>PTSD is common in individuals with HNC; however, the lack of a standardized approach to diagnosing PTSD in patients with and survivors of HNC creates challenges in identifying patients who may benefit from treatment. Given that HNC is the seventh most common cancer worldwide, with increasing incidence, there is a need to better understand the relationship between HNC and PTSD to allow for better PTSD screening, identification, and treatment to improve patients' health-related quality of life and provide optimal patient care.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Impact of MRI-Guided Intracavitary-Interstitial Brachytherapy in the Curative Management of Advanced-Stage Cervical Cancer.","authors":"Antje Wark, Laura Hüfner, Eva Meixner, Jan Oelmann, Laila König, Simon Höne, Katja Lindel, Jürgen Debus, Nathalie Arians","doi":"10.3390/curroncol32030136","DOIUrl":"10.3390/curroncol32030136","url":null,"abstract":"<p><p>This study investigates the clinical efficacy of MRI-based adaptive brachytherapy (IGABT) using combined intracavitary and interstitial techniques in the curative treatment of patients with advanced cervical cancer (LACC). A retrospective analysis was conducted on 149 LACC patients treated at a single center. The therapeutic protocol included intensity-modulated external beam radiotherapy (IMRT) and IGABT. Dosimetric parameters were evaluated for relevance for local control (LC), progression-free survival (PFS), and overall survival (OS) using Kaplan-Meier estimation, Cox regression, and log-rank test. Patients predominantly presented with stage III/IV tumors (81%, FIGO 2018). The median high-risk clinical target volume (hrCTV) was 34 cm³, with a median D90% dose of 88.9 GyEQD2. At 24 months, OS, PFS, and LC rates were 86%, 57%, and 81%, respectively. FIGO stage, tumor volume, and histology were significant predictors of PFS. Higher total hrCTV doses were strongly correlated with improved LC and PFS, emphasizing the importance of precise dosimetric optimization in IGABT and confirming the critical role of IGABT in achieving very good LC rates for LACC. The reported LC rates are comparable to landmark studies, such as INTERLACE and KEYNOTE-A18. This study validates the effectiveness of MRI-guided IGABT in enhancing local tumor control in advanced-stage cervical cancer while providing insights into the prognostic implications of dosimetric parameters such as hrCTV and point A. Future research should address the persistent challenge of distant metastases by exploring the integration of novel systemic treatment options.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Data to Assess the Proportion of Patients Admitted for Febrile Neutropenia That Could Be Considered at Low Risk: The Experience of the Centre Hospitalier Universitaire de Québec.","authors":"Tommy Jean, Camille Sylvestre, Francis Caron, Dominique Leblanc, Geneviève Soucy, Julie Lemieux","doi":"10.3390/curroncol32030133","DOIUrl":"10.3390/curroncol32030133","url":null,"abstract":"<p><p>Febrile neutropenia (FN) is a serious complication of chemotherapy that often leads to hospitalization in cancer patients. It is now well-established that carefully selected patients can be safely treated on an outpatient basis. The objective of this study was to assess the number and proportion of patients hospitalized for FN in a university hospital setting who would have met the low-risk criteria for FN, and whether these patients experienced favorable outcomes during hospitalization. We conducted a retrospective study of all patients admitted for FN at three hospitals in Quebec City between 1 January 2018 and 31 December 2019. Patients with leukemia and those who had undergone stem cell transplants were excluded. A retrospective chart review was performed to establish the Multinational Association for Supportive Care in Cancer (MASCC) score for each patient. Based on predefined criteria, we also determined whether the clinical course was favorable or unfavorable. A total of 177 hospitalizations met our inclusion criteria. We found that 101/177 (57.1%) of the hospitalized patients met the low-risk FN criteria according to their MASCC score. Among these, 74/177 (41.8%) met all the criteria for outpatient treatment. The majority of these patients had a favorable outcome (70/74, 94.6%). In contrast, among patients who did not meet the eligibility criteria for outpatient treatment, 44.7% (46/103) experienced favorable outcomes during their hospitalization. These data highlight the importance of patient selection for outpatient care.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and Acceptability of Social Prescribing for Cancer Survivors.","authors":"Deirdre Connolly, Chloe O'Hara, Catherine O'Brien, Adrienne Dempsey","doi":"10.3390/curroncol32030129","DOIUrl":"10.3390/curroncol32030129","url":null,"abstract":"<p><p>Following cancer treatment, individuals experience a range of physical, mental and social health difficulties that interfere with their ability to resume participation in pre-cancer activities. In Ireland, the National Cancer Strategy recommends community-based services to address post-treatment difficulties. Social prescribing is a community-based, non-medical service that links individuals with health-related activities and supports in their community. This study explored the feasibility and acceptability of social prescribing for cancer survivors. A mixed methods study was undertaken with individuals who had completed curative treatment for any cancer type. Recruitment was carried out in a national cancer centre. Quantitative outcomes included feasibility metrics (recruitment, intervention adherence and retention), the Frenchay Activities Index (FAI), the Hospital Depression and Anxiety Scale (HADS), the Multidimensional Assessment of Fatigue (MAF), and EORTC QLQ-C30. Qualitative interviews explored acceptability of social prescribing. Data were analysed using descriptive statistics (quantitative data) and content analysis (qualitative data). Out of 131 individuals identified as eligible to participate, 43 agreed to participate (32.8% recruitment) and 27 met a link worker and were connected to a local activity (62.7% adherence) and completed follow-up outcome measures (62.7% retention). Improvements were observed in all health-related outcomes and those interviewed identified the intervention as acceptable. Study participants attended a range of community-based activities as a result of link worker support. They also reported increased confidence, improved mental health and reduction in fatigue following attendance at community-based activities. The findings of this study indicate that social prescribing is a feasible and acceptable community-based intervention to improve the physical, mental and social health of individuals living with and beyond cancer. A pilot randomised trial is indicated to inform a definitive intervention trial.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use.","authors":"Joanna Gotfrit, Horia Marginean, Yoo-Joung Ko, Akmal Ghafoor, Petr Kavan, Haji Chalchal, Shahid Ahmed, Karen Mulder, Patricia Tang, Rachel Goodwin","doi":"10.3390/curroncol32030128","DOIUrl":"10.3390/curroncol32030128","url":null,"abstract":"<p><p>Advanced pancreatic cancer results in high morbidity and mortality. The standard of care treatment in the advanced setting changed in 2011 with the introduction of FOLFIRINOX (FFX) chemotherapy. However, it was highly toxic with significant risk of complications. We assessed the practice patterns of medical oncologists across Canada.</p><p><strong>Methods: </strong>We performed a retrospective study of consecutive patients with advanced pancreatic cancer treated with FFX at eight Canadian cancer centers. Demographic, treatment, and outcome data were collected and analyzed.</p><p><strong>Results: </strong>The median age of the patients was 61 (range 24-80), 43% were female, 96% had an ECOG PS of 0 or 1, and 50% had three or more metastatic sites. The median follow-up time was 20.8 months (95%CI 18.6-24.9). Physicians started FFX at the standard dose 31% of the time. Physicians prescribed GCSF for primary prophylaxis most when giving standard-dose FFX (30% of the time) in comparison to reduced dose with or without the 5-FU bolus. Dose reductions occurred in 78.1% of patients, while dose delay occurred in 65.2% of patients.</p><p><strong>Conclusions: </strong>Medical oncologists in Canada historically prescribed FFX to patients with advanced pancreatic cancer in a fashion that was not uniform, prior to the emergence of evidence for upfront dose reductions.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Real-World Evidence of the Economic Burden of Lung Cancer in Greece Exist? A Systematic Review of the Literature.","authors":"George Gourzoulidis, Catherine Kastanioti, George Mavridoglou, Theodore Kotsilieris, Dikaios Voudigaris, Charalampos Tzanetakos","doi":"10.3390/curroncol32030130","DOIUrl":"10.3390/curroncol32030130","url":null,"abstract":"<p><strong>Objective: </strong>This systematic literature review aimed to summarize the economic burden of lung cancer in Greece, identify current data gaps, and support the design of future real-world studies.</p><p><strong>Methods: </strong>A systematic search of studies published in English on the cost of lung cancer was performed in MEDLINE-(PubMed), Scopus, and ScienceDirect. The databases were searched until September 2024, and records were screened based on our eligibility criteria. After conducting the initial literature search, the abstracts and full texts of the identified studies were reviewed and evaluated for inclusion based on predefined criteria. Data from the selected studies were then extracted into a standardized form and subsequently synthesized.</p><p><strong>Results: </strong>Seven studies were included in this review. The reported burden was sourced from hospital data and categorized as direct and indirect costs. Most studies (n = 6) reported direct costs, with one study reporting both direct and indirect costs. The total direct medical cost per patient increased from approximately EUR 16,000 in 2015 to EUR 58,974 in 2023, with drug acquisition costs being the key driver of the total direct cost. Additionally, the cost of end-of-life care during the final six months of a patient's life was estimated to range from EUR 6786 to EUR 7665 per patient, with pharmaceutical costs comprising the largest proportion of the total cost. One study also reported that indirect costs were considerably higher for patients than for family caregivers.</p><p><strong>Conclusion: </strong>The economic burden of lung cancer has increased substantially over the past decade in Greece. The present systematic review emphasizes the critical need for comprehensive real-world studies on the economic burden of lung cancer in Greece. Addressing the current gaps holistically will yield invaluable insights for policymakers and stakeholders.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Adrenal Metastases in Prostate Cancer Patients with [68GA]GA-PSMA PET/CT Imaging.","authors":"Ebuzer Kalender, Edanur Ekinci, Umut Elboğa, Ertan Şahin","doi":"10.3390/curroncol32030127","DOIUrl":"10.3390/curroncol32030127","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the imaging and clinical characteristics of adrenal metastases detected by [68Ga]Ga-PSMA PET/CT in prostate cancer patients, with a focus on diagnostic accuracy and prognostic implications. Specifically, we examined the correlation between adrenal lesion characteristics and prognostic markers, such as prostate-specific antigen (PSA) levels and Gleason scores. This study also assessed the diagnostic performance of PSA, standardized uptake value maximum (SUVmax), and Hounsfield Unit (HU) values in differentiating adrenal metastases from benign adrenal adenomas.</p><p><strong>Materials and methods: </strong>This retrospective study included 44 prostate cancer patients with adrenal lesions identified using [68Ga]Ga-PSMA PET/CT between January 2020 and October 2024. The patients were categorized into two groups: benign adrenal adenomas (<i>n</i> = 16) and adrenal metastases (<i>n</i> = 28). The PET/CT imaging was performed using a 5-ring Discovery IQ PET/CT scanner with QClear reconstruction, following the injection of 2.5 MBq/kg [68Ga]Ga-PSMA ligand and a standardized uptake time of 60 min. The imaging parameters (SUVmax and HU values), clinical characteristics (PSA levels, Gleason scores, and presence of lymphadenopathy), and patient outcomes were analyzed. A ROC analysis was conducted to evaluate the diagnostic performance of these key parameters.</p><p><strong>Results: </strong>Patients with adrenal metastases had significantly higher PSA levels (mean: 45.6 ± 12.4 ng/mL vs. 18.3 ± 6.7 ng/mL; <i>p</i> < 0.01) and Gleason scores (median: 8 vs. 6; <i>p</i> < 0.01) than those with benign adenomas. SUVmax values were significantly elevated in metastatic lesions (mean: 12.8 ± 4.3 vs. 3.4 ± 1.2; <i>p</i> < 0.001), and HU values were also higher (mean: 45 ± 15 vs. 18 ± 10; <i>p</i> < 0.01). The ROC analysis revealed that SUVmax had the highest diagnostic accuracy (AUC: 0.87), followed by PSA (AUC: 0.85) and HU (AUC: 0.80). Disease progression was observed in 67.9% of metastatic cases versus 18.8% in the adenoma group (<i>p</i> < 0.001), and median overall survival was shorter in metastatic cases (24 months vs. 38 months; <i>p</i> < 0.01).</p><p><strong>Conclusions: </strong>[68Ga]Ga-PSMA PET/CT is a valuable imaging modality for distinguishing adrenal metastases from benign adenomas in prostate cancer patients. The integration of PSA, SUVmax, and HU values into diagnostic workflows enhances diagnostic precision and improves clinical decision-making. Future research should focus on the prospective validation of these findings in larger cohorts and explore artificial intelligence-based approaches for automated lesion characterization.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obstructive Jaundice Induced by Hilar Mucinous Cystic Neoplasm of the Liver: A Rare Case Report and Literature Review.","authors":"Pengcheng Wei, Shengmin Zheng, Chen Lo, Yongjing Luo, Liyi Qiao, Jie Gao, Jiye Zhu, Yi Wang, Zhao Li","doi":"10.3390/curroncol32030126","DOIUrl":"10.3390/curroncol32030126","url":null,"abstract":"<p><p>Mucinous cystic neoplasm of the liver (MCN-L) is a rare benign tumor accounting for less than 5% of all liver cysts, with MCN-L in the hilar region being exceptionally uncommon and often misdiagnosed due to its complex presentation. A 48-year-old woman presented with obstructive jaundice following initial laparoscopic drainage of hepatic cysts, where pathology initially indicated benign cystic lesions. Months later, imaging revealed an enlarged cystic lesion in the left liver lobe with intrahepatic bile duct dilation. Further evaluations, including ultrasound, enhanced CT, and MRI, confirmed a large cystic lesion compressing the intrahepatic bile ducts. After a multidisciplinary discussion, hepatic cyst puncture and drainage were performed, temporarily alleviating jaundice. However, she returned with yellowish-brown drainage fluid and worsening jaundice, prompting cyst wall resection. Postoperative pathology confirmed MCN-L. Three months later, jaundice subsided, and a hepatic resection of segment 4 was performed, with pathology confirming low-grade MCN-L. At a 12-month follow-up, the patient showed no abnormalities. This case highlights the diagnostic and therapeutic challenges of MCN-L in the hilar region, as it can easily be mistaken for other liver cystic lesions on imaging. Pathologic examination is essential for definitive diagnosis, and early radical surgical resection is critical to improve prognosis and reduce the risk of malignancy and recurrence.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When \"One Size Fits All\" Fits None: A Commentary on the Impacts of the\"Draft Canadian Breast Cancer Screening Guidelines\" on Racialized Populations in Canada.","authors":"Beverley Osei, Gayathri Naganathan, Juliet M Daniel, Supriya Kulkarni, Aisha Lofters, Yinka Oladele, Leila Springer, Mojola Omole","doi":"10.3390/curroncol32030123","DOIUrl":"10.3390/curroncol32030123","url":null,"abstract":"<p><p>Epidemiological data show racial and ethnic differences exist in breast cancer morbidity and mortality amongst Black, Indigenous, Asian, and Hispanic populations, with non-white females experiencing earlier age at diagnosis, more aggressive breast cancer subtypes and advanced cancer stages, and earlier mortality than white females. However, the current Canadian breast cancer screening guidelines recommend biannual screening for all females starting from age 50 to age 74 and suggest not to screen individuals aged 40-49. In May 2024, the Canadian Task Force for Preventative Health released updated draft breast cancer screening guidelines, maintaining such recommendations for screening. Both the existing and the proposed guidelines fail to account for the unique cancer burden amongst racialized populations in Canada and risk further perpetuation of existing racial and ethnic disparities by underscreening racialized females. This commentary will present data regarding racial disparities in cancer burden, highlighting the role social and biological factors play in impacting cancer risk and age of disease and presenting perspectives from stakeholder groups reflecting the impacts of current screening guidelines. Ultimately, we critique the current \"one-size-fits-all\" approach to breast cancer screening in Canada, emphasizing the need for adapted screening practices with the understanding that the current approaches overlook the needs of racialized Canadian populations.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}